tiprankstipranks
BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials
Company Announcements

BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials

Bioline RX Ltd Sponsored ADR (BLRX) has released an update.

Don't Miss our Black Friday Offers:

BioLineRx Ltd has announced promising results from a Phase 1 clinical trial evaluating motixafortide for mobilizing stem cells in patients with sickle cell disease. The study suggests that motixafortide, alone or combined with natalizumab, can effectively mobilize the necessary stem cells for gene therapies in a single apheresis cycle. These findings could potentially enhance the treatment process and accessibility of gene therapy for individuals with sickle cell disease.

For further insights into BLRX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskBioLineRx Reports Strategic Moves in Q3 2024
TheFlyBioLineRx price target lowered to $9 from $21 at H.C. Wainwright
TipRanks Auto-Generated NewsdeskBioLineRx Secures Key Deals to Boost Shareholder Value
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App